IgA nephropathy
Travere Fights for FDA Approval Despite Filspari’s Trial Endpoint Miss
Travere Therapeutics has recently encountered setbacks in two critical trials involving their drug Filspari, with implications for its accelerated approval ...
Novartis’ $3.2B Chinook Investment Soars with Successful Phase 3 Endpoint, Paving the Way for 2024 FDA Filing
Novartis is seeing promising results from its substantial $3.2 billion investment in Chinook Therapeutics. Exciting top-line data from a phase ...
Omeros halts phase 3 trial of kidney disease drug after disappointing results, stock plummets
In a surprising turn of events, Omeros has halted its phase 3 trial of narsoplimab in kidney disease patients, as ...
Novartis’ iptacopan impresses in phase 3 trial for rare kidney disease
Novartis is celebrating a significant achievement as its investigational oral factor B inhibitor reaches a crucial milestone in a phase ...
FDA Awards Priority Review for Full Approval of Tarpeyo in Treating IgA Nephropathy
Calliditas Therapeutics, a leading pharmaceutical company, has exciting news to share. The U.S. Food and Drug Administration (FDA) has accepted ...
Vera Therapeutics Atacicept Shows Efficacy and Safety in IgAN at ERA Congress
Soure: Vera Therapeutics On June 17, 2023, Vera Therapeutics, a biotechnology company focused on immunological diseases, announced positive results from ...
